Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrosis and related diseases. Fibrosis is a process of scarring that occurs in many organs, and can lead to serious medical conditions such as liver cirrhosis, pulmonary fibrosis, and kidney fibrosis.
Pliant's lead product candidate, PLN-74809, is a small molecule inhibitor of integrin αVβ1, a key driver of fibrosis. PLN-74809 is currently in phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), and is also being evaluated for the treatment of liver fibrosis and other fibrotic diseases.
Pliant has a pipeline of additional product candidates targeting various fibrotic pathways, including integrins, TGF-β, and lysyl oxidase-like 2 (LOXL2).
The company is headquartered in South San Francisco, California and was founded in 2016.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrosis and related diseases. Fibrosis is a process of scarring that occurs in many organs, and can lead to serious medical conditions such as liver cirrhosis, pulmonary fibrosis, and kidney fibrosis.